Status | Study |
Completed |
Study Name: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Condition: Lymphoma, T-Cell, Cutaneous Date: 2011-11-29 Interventions: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |
Active, not recruiting |
Study Name: A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) Condition: Lymphoma, T-cell, Peripheral Date: 2011-10-18 Interventions: Drug: Romidepsin Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle |
Completed |
Study Name: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) Condition: Lymphoma, T-Cell, Cutaneous Date: 2011-09-09 Interventions: Drug: placebo for SHAPE (SHP-141) |
Recruiting |
Study Name: T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2010-06-10 |
Recruiting |
Study Name: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Condition: Cutaneous T Cell Lymphoma Date: 2010-05-25 Interventions: Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Completed |
Study Name: Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma Condition: T-cell Lymphoma Date: 2009-08-14 Interventions: Drug: Bendamustine Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 day |
Terminated |
Study Name: CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Condition: T-cell Lymphoma Date: 2009-05-05 Interventions: Biological: CHOP + CD4 Drug: CHOP |
Completed |
Study Name: Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma Condition: T Cell Lymphoma Date: 2008-11-21 Interventions: Drug: Fostamatinib Disodium 200 mg PO BID Other Name |
Recruiting |
Study Name: Alemtuzumab and CHOP in T-cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2008-02-14 Interventions: Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin |
No longer available |
Study Name: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) Condition: Lymphoma, T-Cell, Cutaneous Date: 2007-01-05 Interventions: Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat |